title: Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma.
abstract: High-dose therapy followed by autologous hematopoietic stem-cell transplantation is the preferred therapy for relapsed chemotherapy-sensitive aggressive non-Hodgkin lymphoma, and may play a role in the treatment of high-risk first-remission aggressive lymphomas, mantle-cell lymphomas and relapsed follicular lymphomas. The primary cause of failure of this approach is disease recurrence despite initial responses. Traditional high-dose regimens have relied upon myeloablative combinations of chemotherapy with or without total body irradiation. In the Western world, over 90% of lymphomas are of B-cell origin, and the vast majority of those that come to transplant remain CD20-positive. The development of radioimmunotherapeutic approaches targeting this antigen allows for either dose escalation with stem-cell support, or the addition of targeted therapy to conditioning regimens either as a replacement for total body irradiation or in addition to myeloablative chemotherapy regimens. Results to date with yttrium-90 ibritumomab tiuxetan (Zevalin) and I-131 tositumomab (Bexxar) suggest that the addition of radioimmunoconjugate therapy to conventional conditioning regimens results in a toxicity profile similar to that seen with chemotherapy conditioning alone. Demonstration of improved disease control will ultimately require phase-III studies, though preliminary results are promising.
authors.affiliation: Mayo Clinic College of Medicine, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA. Inwards.David@Mayo.edu
authors.forename: David J
authors.initials: DJ
authors.lastname: Inwards
authors.forename: Jeffrey C
authors.initials: JC
authors.lastname: Cilley
authors.forename: Jane N
authors.initials: JN
authors.lastname: Winter
mesh_terms: D004307:Dose-Response Relationship, Radiation; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D016499:Radioimmunotherapy / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018796:Immunoconjugates